Thelansis

Vulvovaginal Candidiasis (VVC) Market Outlook Thelansis’s “Vulvovaginal Candidiasis (VVC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vulvovaginal Candidiasis (VVC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact o...

Vulvovaginal Candidiasis (VVC) Market Outlook Thelansis’s “Vulvovaginal Candidiasis (VVC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vulvovaginal Candidiasis (VVC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Vulvovaginal Candidiasis (VVC) Overview Vulvovaginal Candidiasis (VVC) occurs when Candida species superficially penetrate the mucosal lining of the vagina and cause an inflammatory response. The dominant inflammatory cells are typically polymorphonuclear cells and macrophages. Patients may present with discharge, which is usually thick and adherent, excoriations, external dysuria, vaginal itching, vaginal burning...

  Vulvovaginal Candidiasis (VVC) occurs when Candida species superficially penetrate the mucosal lining of the vagina and cause an inflammatory response. The dominant inflammatory cells are typically polymorphonuclear cells and macrophages. Patients may present with discharge, which is usually thick and adherent, excoriations, external dysuria, vaginal itching, vaginal burning, dyspareunia, or swelling. Risk factors for acute candidal vulvovaginitis include estrogen use, elevated endogenous estrogens, diabetes mellitus, immunosuppression, and broad-spectrum antibiotic use. Although candidal vulvovaginitis is more common in sexually active women, there is no evidence that candidal infection is sexually transmitted. Patients with recurrent candidal vulvovaginitis have predisposing genetic factors that cause them to be susceptible to recurrent fungal infections. These factors may also predispose to hypersensitivity to Candida. The most common responsible pathogen is C. albicans (in ...